Compare with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CIPLA ALKEM LABORATORIES/
CIPLA
 
P/E (TTM) x - 23.2 - View Chart
P/BV x 6.6 2.4 275.8% View Chart
Dividend Yield % 0.7 0.7 97.7%  

Financials

 ALKEM LABORATORIES   CIPLA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CIPLA
Mar-19
ALKEM LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,589678 234.4%   
Low Rs1,232484 254.7%   
Sales per share (Unadj.) Rs417.5198.2 210.6%  
Earnings per share (Unadj.) Rs56.318.5 303.9%  
Cash flow per share (Unadj.) Rs64.735.0 185.0%  
Dividends per share (Unadj.) Rs12.703.00 423.3%  
Dividend yield (eoy) %0.90.5 174.3%  
Book value per share (Unadj.) Rs292.9186.3 157.2%  
Shares outstanding (eoy) m119.57805.70 14.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.9 115.3%   
Avg P/E ratio x25.131.4 79.9%  
P/CF ratio (eoy) x21.816.6 131.3%  
Price / Book Value ratio x4.83.1 154.4%  
Dividend payout %22.616.2 139.3%   
Avg Mkt Cap Rs m168,653468,031 36.0%   
No. of employees `000NA22.6 0.0%   
Total wages/salary Rs m9,17128,565 32.1%   
Avg. sales/employee Rs ThNM7,053.1-  
Avg. wages/employee Rs ThNM1,261.5-  
Avg. net profit/employee Rs ThNM659.1-  
INCOME DATA
Net Sales Rs m49,915159,710 31.3%  
Other income Rs m1,6454,766 34.5%   
Total revenues Rs m51,561164,475 31.3%   
Gross profit Rs m8,48230,973 27.4%  
Depreciation Rs m1,00613,263 7.6%   
Interest Rs m6711,684 39.8%   
Profit before tax Rs m8,45120,791 40.6%   
Minority Interest Rs m-114-172 66.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6065,695 28.2%   
Profit after tax Rs m6,73114,924 45.1%  
Gross profit margin %17.019.4 87.6%  
Effective tax rate %19.027.4 69.4%   
Net profit margin %13.59.3 144.3%  
BALANCE SHEET DATA
Current assets Rs m27,062124,266 21.8%   
Current liabilities Rs m15,32437,715 40.6%   
Net working cap to sales %23.554.2 43.4%  
Current ratio x1.83.3 53.6%  
Inventory Days Days6791 73.4%  
Debtors Days Days4195 43.5%  
Net fixed assets Rs m12,610105,190 12.0%   
Share capital Rs m2391,611 14.8%   
"Free" reserves Rs m34,490148,511 23.2%   
Net worth Rs m35,027150,123 23.3%   
Long term debt Rs m1,21238,301 3.2%   
Total assets Rs m54,387239,633 22.7%  
Interest coverage x13.613.3 101.9%   
Debt to equity ratio x00.3 13.6%  
Sales to assets ratio x0.90.7 137.7%   
Return on assets %13.66.9 196.4%  
Return on equity %19.29.9 193.3%  
Return on capital %24.911.8 210.0%  
Exports to sales %12.934.7 37.3%   
Imports to sales %3.10-   
Exports (fob) Rs m6,46155,419 11.7%   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56357,410 11.4%   
Fx outflow Rs m3,01219,041 15.8%   
Net fx Rs m3,55238,368 9.3%   
CASH FLOW
From Operations Rs m7,25916,911 42.9%  
From Investments Rs m1,864-16,687 -11.2%  
From Financial Activity Rs m-9,273-3,487 265.9%  
Net Cashflow Rs m-150-3,451 4.3%  

Share Holding

Indian Promoters % 66.9 16.0 418.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 33.1 12.2 271.3%  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 0.0 26.2 -  
Shareholders   68,381 161,166 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  FDC LTD.  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)

Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Oct 16, 2019 01:31 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS